

2020-12-18

Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) -lactamase enzymes in *Acinetobacter baumannii*

Takebayashi, Y

<http://hdl.handle.net/10026.1/16801>

10.1093/jac/dkaa502

Journal of Antimicrobial Chemotherapy

Oxford University Press (OUP)

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

**Variability in carbapenemase activity of intrinsic OxaAb
 (OXA-51-like) beta-lactamase enzymes in *Acinetobacter
 baumannii***

Journal:	<i>Journal of Antimicrobial Chemotherapy</i>
Manuscript ID	JAC-2020-1311.R2
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Takebayashi, Yuiko; University of Bristol, School of Cellular & Molecular Medicine Findlay, Jacqueline; University College London Faculty of Medical Sciences, Division of Infection & Immunity Heesom, Kate; University of Bristol, Bristol Proteomics Facility Warburton, Philip; University of Plymouth, School of Biomedical and Healthcare Science Avison, Matthew; University of Bristol, Department of Cellular & Molecular Medicine; Evans, Benjamin; University of East Anglia, Medical Microbiology
Keywords:	OXA-type beta-lactamase, Carbapenems, MIC, Antimicrobial resistance

SCHOLARONE™
 Manuscripts

1 **Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) beta-lactamase**
2 **enzymes in *Acinetobacter baumannii***

3
4 **Yuiko Takebayashi^{1,2*}, Jacqueline Findlay^{2,3}, Kate J. Heesom⁴, Philip J. Warburton^{1,5}, Matthew**
5 **B. Avison², Benjamin A. Evans^{1,6}**

6
7 **¹Department of Biomedical and Forensic Science, Anglia Ruskin University, Cambridge, UK**

8 **²School of Cellular and Molecular Medicine, University of Bristol, UK**

9 **³Division of Infection & Immunity, Faculty of Medical Sciences, University College London, UK**

10 **⁴Bristol Proteomics Facility, University of Bristol, Bristol. UK.**

11 **⁵School of Biomedical Sciences, Faculty of Health, University of Plymouth, UK**

12 **⁶Norwich Medical School, University of East Anglia, UK**

13

14 ***Correspondence: Yuiko Takebayashi, School of Cellular and Molecular Medicine, Biomedical**
15 **Sciences Building, University Walk, Bristol, UK, BS8 1TD. yuiko.takebayashi@bristol.ac.uk.**
16 **+44(0)117 331 2037.**

17 **Running heading: Carbapenemase activity of intrinsic OxaAb**

18 ABSTRACT

19 Objectives

20 This study aimed to measure the variability in carbapenem susceptibility conferred by different
21 OxaAb variants, characterise the molecular evolution of *oxaAb* and elucidate the contribution
22 of OxaAb and other possible carbapenem resistance factors in the clinical isolates using WGS
23 and LC-MS/MS.

24 Methods

25 Antimicrobial susceptibility tests were performed on ten clinical *A. baumannii* isolates.
26 Carbapenem MICs were evaluated for all *oxaAb* variants cloned into *A. baumannii* CIP70.10 and
27 BM4547, with and without their natural promoters. Molecular evolution analysis of the *oxaAb*
28 variants was performed using FastTree and SplitsTree4. Resistance determinants were studied
29 in the clinical isolates using WGS and LC-MS/MS.

30 Results

31 Only the OxaAb variants with I129L and L167V substitutions, OxaAb(82), OxaAb(83),
32 OxaAb(107), and OxaAb(110) increased carbapenem MICs when expressed in susceptible *A.*
33 *baumannii* backgrounds without an upstream IS element. Carbapenem resistance was
34 conferred with the addition of their natural upstream *ISAba1* promoter. LC-MS/MS analysis on
35 the original clinical isolates confirmed overexpression of the four I129L and L167V variants. No
36 other differences in expression levels of proteins commonly associated with carbapenem
37 resistance were detected.

38 **Conclusions**

39 Elevated carbapenem MICs were observed by expression of OxaAb variants carrying clinically
40 prevalent substitutions I129L and L167V. To drive carbapenem resistance, these variants
41 required overexpression by their upstream *ISAba1* promoter. This study clearly demonstrates
42 that a combination of IS-driven overexpression of *oxaAb* and the presence of particular amino
43 acid substitutions in the active site to improve carbapenem capture is key in conferring
44 carbapenem resistance in *A. baumannii* and other mechanisms are not required.

46 INTRODUCTION

47 Carbapenem-resistant *Acinetobacter baumannii* is a World Health Organisation (WHO) priority
48 level one pathogen, commonly associated with nosocomial infections in ICUs.^{1,2} Once treatable
49 with broad-spectrum cephalosporins such as ceftazidime and cefepime, heavy usage of these
50 antibiotics has led to the reliance and subsequent resistance to last-resort carbapenem
51 treatment. *A. baumannii* are notorious for their genetic plasticity, enabling them to acquire
52 resistance genes from *Pseudomonas aeruginosa* and clinically relevant Enterobacterales such as
53 *Escherichia coli* and *Klebsiella pneumoniae*. Clinical *A. baumannii* have been reported to carry
54 multiple acquired β -lactamases from all four Class A-D molecular groups such as TEM, CARB,
55 PER, GES, VEB, CTX-M, IMP, VIM, NDM and OXA to varying frequencies, in addition to the
56 intrinsic AmpC (ADC) and OxaAb (OXA-51-like) enzymes.³⁻⁶ Upregulation of some of these β -
57 lactamases by means of insertion sequences (IS) such as IS*Aba1* and IS*Aba125* have also driven
58 this resistance phenomenon.⁷⁻⁹

59 The main mechanism for carbapenem resistance in *A. baumannii* is carbapenem-hydrolysing
60 class D β -lactamases, most commonly Oxa23, Oxa40, OxaAb, Oxa58, Oxa143 and Oxa235
61 groups, frequently associated with IS elements.¹⁰⁻¹⁵ Characterisation of clinical isolates has also
62 inferred the synergistic importance of the upregulation of multidrug efflux pumps (notably the
63 RND transporters AdeABC and AdeIJK) and the loss of certain porins (CarO, Omp33-36, OmpA
64 and OmpW).¹⁶⁻²² However, the extent in which these proteins and their production levels play a
65 role in carbapenem resistance is not yet clear. In recent years there has been a concerted effort
66 to fill these gaps in our understanding of the factors contributing to carbapenem resistance
67 phenotypes in *A. baumannii* using WGS, whole transcriptome shotgun sequencing (RNA-Seq)

68 and proteomic approaches. However, these studies have not always been consistent with one
69 another - in some cases carbapenem-resistant strains were shown to overexpress efflux pumps
70 and downregulate porins^{17,20}, whereas in others, carbapenem resistance was associated with an
71 increase in porin abundance.¹⁸ These inconsistencies demonstrate that our understanding of
72 the interplay between resistance mechanisms in *A. baumannii* remains incomplete.

73 OxaAb enzymes are intrinsic and by far the largest group of OXAs in *A. baumannii*, with 320
74 variants identified as of 03/06/2020.²³ When OxaAb variants are characterised in clinical
75 carbapenem resistant isolates worldwide, the presence of *ISAbal* upstream is frequently noted
76 and this has led to the general acceptance that transcriptional upregulation of these enzymes
77 by upstream IS insertion, providing a strong promoter, can confer carbapenem resistance in the
78 absence of other β -lactamases. However, it is unclear whether only specific variants (e.g.
79 OxaAb(138) and OxaAb(82)^{24,25}) confer this phenotype or if overproduction of all OxaAb types
80 can lead to carbapenem resistance. Studies from the last few years of the effect of specific
81 amino acid substitutions in OxaAb, for example at Ile-129, Leu-167 and Trp-222, have
82 demonstrated that this can alter the enzyme structure and significantly increase catalytic
83 activity with respect to the carbapenems.²⁶⁻²⁹ However, the impact of such substitutions alone
84 on the antibiotic susceptibility of bacteria is unclear. Recent papers have highlighted clinical
85 isolates carrying *ISAbal/oxaAb* genes that do not exhibit carbapenem resistance.^{30,31} Nigro and
86 Hall also elude to differences in carbapenem MIC depending on the OxaAb variant and/or other
87 intrinsic factors in different backgrounds.³¹ In order to address some of these stated unknowns
88 concerning carbapenem resistance in *A. baumannii*, this study aimed to i) measure the
89 variability in carbapenem MIC conferred by different OxaAb variants, ii) characterise the

- 90 molecular evolution of *oxaAb* and iii) elucidate the contribution of OxaAb and other possible
91 carbapenem resistance determinants in clinical isolates using WGS and LC-MS/MS proteomics.

Confidential: for peer review only

93 MATERIALS AND METHODS

94 Bacterial strains and antimicrobial susceptibility testing

95 Ten clinical *A. baumannii* isolates were used in this study (**Table 1**). Imipenem and meropenem
96 MICs were previously characterised by Evans *et al* (except isolates B1 and A403), as well as the
97 identification of IS*Abal* elements upstream of their respective *oxaAb* genes.³² Recombinants
98 were made using the following strains: *E. coli* DH5 α (Subcloning Efficiency DH5 α Competent
99 cells, Invitrogen, United Kingdom), *A. baumannii* CIP70.10 and BM4547³³ (gifts from Laurent
100 Poirel, University of Fribourg). The presence of the spontaneous mutation P116L in *adeR* of
101 BM4547 responsible for increasing the AdeABC efflux pump expression was confirmed by PCR
102 and sequencing using primers R-am and R-av³³. Disc susceptibility and MIC broth microdilution
103 tests were performed and interpreted according to CLSI guidelines.³⁴

104 WGS

105 Genomes were sequenced by MicrobesNG on a HiSeq 2500 instrument (Illumina, San Diego, CA,
106 USA) as previously described.³⁵ Insertion Sequences (IS) were identified using ISFinder.³⁶

107 Proteome analysis via Orbitrap LC-MS/MS

108 Total cell extractions of the clinical isolates (in three biological replicates) were prepared and 1
109 μ g of each sample was analysed using an Orbitrap Velos mass spectrometer (Thermo Fisher
110 Scientific) and quantified using Proteome Discoverer software v1.4 (Thermo Fisher Scientific) as
111 outlined previously.³⁵ The raw data files were searched against the UniProt *A. baumannii* ACIBA
112 database (67,615 protein entries) and an in-house mobile resistance determinant database.³⁷

113 Abundance values of each protein were converted to ratios relative to the average abundance
114 of 30S and 50S ribosomal proteins, for ease of comparison between isolates.

115 Cloning and transformations

116 The genes for the *oxaAb* variants encoding OxaAb(64), (65), (66), (69), (71), (82), (83), (107),
117 (110) and (111) were PCR amplified from clinical *A. baumannii* isolates (with additional NcoI and
118 XhoI sites introduced at the 5' and 3' ends respectively) using OXA-66-NcoI F, OXA-111-NcoI F
119 or OXA-71-NcoI F and OXA-66-XhoI R primers (**Table 2**) and TA cloned into the vector pGEM-T
120 Easy (Promega, United Kingdom). The inserts were confirmed by sequencing with the universal
121 T7 Promoter primer. For transformation into *E. coli* DH5 α , *A. baumannii* CIP70.10 and BM4547,
122 the inserts were digested with NcoI and XhoI and ligated into pYMAb2, a pET-28a vector with
123 plasmid replicon fragments RepM and Ori from *A. baumannii* plasmid pMAC and an *oxa72*
124 promoter region subcloned from a clinical isolate with no presence of ISAbal1 (a gift from Dr Te-
125 Li Chen, National Defense Medical Center, Taiwan).³⁸ For genes including their natural
126 upstream promoter regions, inserts were PCR amplified using OXA-51-like_XbaI F or
127 ISAbal1_XbaI F and OXA-51-like_EcoRI R primers, digested with XbaI and EcoRI and ligated into
128 pUBYT,³⁷ a pYMAb2-derived vector with the *oxa72* promoter region deleted. All inserts were
129 confirmed by sequencing using the pYMAb2 Check primers (**Table 2**).

130 All plasmids were used to transform *E. coli* DH5 α and *A. baumannii* CIP70.10 and BM4547
131 strains by electroporation. Transformants were selected with ampicillin (100 mg/L) and
132 ChromoMax IPTG/X-Gal (Fisher BioReagents, United Kingdom) for pGEM-T Easy recombinants
133 or kanamycin (50 mg/L) for pYMAb2 and pUBYT recombinants.

134 Predicting the molecular evolution of *OxaAb* variants

135 The nucleotide sequence of *oxaAb(66)* was used to query the NCBI nucleotide and genome
136 databases using BLAST, implemented in Geneious (<https://www.geneious.com>), and all
137 available *oxaAb* sequences were downloaded. The sequence for the gene of the naturally-
138 occurring OXA from *Acinetobacter calcoaceticus* (*oxa213*) was included as an outgroup.³⁹
139 Duplicate sequences were removed and remaining sequences aligned. A maximum likelihood
140 phylogeny of the *oxaAb* genes was estimated using FastTree. Support for the resulting
141 phylogeny was estimated using 100 bootstraps. The Phi test was used to detect recombination
142 within the *oxaAb* alignment using SplitsTree4.⁴⁰ A translation of the nucleotide alignment was
143 used to identify all OXAs that were different from the consensus sequence at Ile-129 and Leu-
144 167 that have previously been described as being important for substrate specificity and
145 hydrolytic activity.^{26,27,41}

147 **RESULTS AND DISCUSSION**148 *Characterisation of β -lactam susceptibility in selected clinical isolates*

149 Ten clinical isolates³² (**Table 1**) were chosen for encoding various OxaAb enzymes that are
150 representative of global clones (GC) 1 and 2 (OxaAb(69) and OxaAb(66) respectively). Some of
151 these isolates (A371, A404, A403 and A443) were also chosen for encoding variants containing
152 substitutions at sites considered important for substrate specificity (I129L in OxaAb(83) and
153 OxaAb(110), and L167V in OxaAb(82) and OxaAb(107) respectively). Others (A60, A37 and
154 A135) were chosen to represent sites where polymorphisms have arisen more than once across
155 the OxaAb phylogeny (E36V/D/K, with OxaAb(65) carrying the consensus Glu-36, and Q194P in
156 OxaAb(64) and OxaAb(111) respectively).^{26,27,41}

157 β -lactam susceptibility results for the clinical isolates are shown in **Table 3**. All isolates were not
158 susceptible to ceftriaxone and cefotaxime except for A135. The four isolates encoding variants
159 with substitutions I129L and L167V (A404, A371, A443 and A403) were non-susceptible to all
160 tested antibiotics, including the carbapenems. WGS did not detect any other β -lactamases
161 known to confer carbapenem resistance.

162 **Table 1** summarises the carbapenem MICs and the designation of IS elements upstream of β -
163 lactamase genes based on the WGS data. Seven *bla*_{ampC} and four *oxaAb* genes had upstream IS
164 elements. IS-driven overproduction of AmpC and OxaAb enzymes was confirmed by analysis of
165 whole cell extracts of the clinical isolates and reference strain CIP70.10 in triplicate via LC-
166 MS/MS (**Figure 1a, 1b**). AmpC variants in CIP70.10, A90, B1 and A135 did not have an upstream

167 IS element and this was associated with enzyme levels below the level of detection. The AmpC
168 enzyme in A230 was the only variant with *ISAb_a125* upstream and displayed the lowest
169 abundance amongst the seven variants with an IS element upstream. This implies that the
170 promoter in *ISAb_a1* is stronger than in *ISAb_a125*. Likewise, only the *oxaAb* genes in
171 carbapenem-resistant isolates A403, A371, A443 and A404 with upstream IS elements
172 produced detectable levels of enzyme. This confirms that without an IS element upstream of an
173 *oxaAb* gene, there is very little expression and hence, negligible contribution to intrinsic
174 resistance.

175 *OxaAb* variants *OxaAb*(82), (83), (107), and (110) increase carbapenem MICs

176 To determine whether substitutions at Ile-129 and Leu-167 in *OxaAb* contribute to the
177 observed carbapenem resistance in isolates A404, A371, A443 and A403, all *oxaAb* genes from
178 the 10 clinical isolates were cloned in the absence of their native promoter, all downstream of
179 the same *Oxa24*(72) promoter carried by pYMAb2. This was to exclude any confounding effects
180 on differential gene expression of upstream IS elements seen in the clinical isolates.

181 In an *A. baumannii* CIP70.10 background (representing a susceptible host), *OxaAb* variants with
182 a substitution at either Ile-129 or Leu-167 allowed for significantly increased carbapenem MICs
183 over the other *OxaAb* variants (t-test, meropenem: $p = 0.0196$, imipenem: $p = 0.0131$) (Table 4).

184 The same was true in the *A. baumannii* BM4547 background, which has increased *adeABC*
185 efflux pump gene expression³³ (t-test, meropenem: $p = 0.0239$, imipenem: $p = 0.0391$). Only
186 *OxaAb*(82) conferred meropenem resistance (8 mg/L) in both backgrounds. The presence of
187 *OxaAb*(107) and (83) increased meropenem MIC to an intermediate phenotype (4 mg/L) in

188 CIP70.10 and BM4547 respectively. While there appeared to be a slight increase in MIC in the
189 BM4547 background compared to the CIP10.10 background of the same magnitude observed in
190 previous studies⁴², this was not statistically significant (t-test, meropenem: $p = 0.9209$,
191 imipenem: $p = 0.6887$). We therefore conclude that the Ile-129 or Leu-167 substitutions seen in
192 OxaAb(82), (83), (107) and (110), increase carbapenem MIC but not to the level of resistance
193 seen in the clinical isolates producing these variants. Furthermore, AdeABC overproduction is
194 not important for carbapenem MICs in strains producing these OxaAb variants.

195 *ISAbal-driven expression of oxaAb only confers carbapenem resistance for certain oxaAb*
196 *variants*

197 The *oxaAb* variants were next cloned into pUBYT with their natural upstream promoter, to
198 identify if the presence of upstream IS elements can enhance MICs and confer carbapenem
199 resistance. Genes encoding three enzymes (OxaAb(82), (107), (110)) with changes at positions
200 Ile-129 or Leu-167, had natural promoters provided by *ISAbal1*, while the remaining *oxaAb*
201 genes had the native chromosomal promoter without the presence of an insertion sequence.
202 Transformation of OxaAb(83) was not achieved despite multiple attempts.

203 When expressed in CIP70.10, the carbapenem MICs against transformants encoding *oxaAb* with
204 an *ISAbal1* promoter increased to resistant levels seen in their parent clinical isolates (**Table 4**).
205 These were significantly higher than the MICs obtained for the other *oxaAb* variants (t-test,
206 meropenem – $p = 9.99 \times 10^{-12}$, imipenem – $p = 1.45 \times 10^{-4}$) where clinical resistance was not
207 reached. While there was an overall increase in meropenem MICs for all transformants under
208 the control of their native promoters compared to the pYMAb2 promoter (t-test, meropenem –

209 $p = 0.0465$, imipenem – $p = 0.0817$), significantly higher MICs were observed for the three
210 transformants encoding *oxaAb* with an *ISAbal* promoter (t-test, meropenem – $p = 0.0009$,
211 imipenem – $p = 0.0319$). This demonstrates that the addition of *ISAbal* upstream of *oxaAb*
212 variants encoding I129L or L167V substitutions confers carbapenem resistance in a recombinant
213 background without any other resistance determinants. When the *oxaAb* variants were cloned
214 into BM4547, the same pattern was also observed and there was no overall difference in the
215 MIC values between the CIP70.10 and BM4547 backgrounds (t-test, meropenem: $p = 0.9700$,
216 imipenem: $p = 0.2391$). Therefore, the increase in AdeABC efflux does not have a crucial role in
217 conferring carbapenem resistance in the context of these OxaAb variants.

218 It is worth noting that the recombinants with upstream *ISAbal* were very difficult to obtain,
219 with extremely low transformation efficiency in both CIP70.10 and BM4547. Plasmid-mediated
220 carriage of these variants with upstream *ISAbal* may be deleterious to the host's fitness and
221 may possibly be the reason for certain variants not being observed to be plasmid-borne in
222 nature.

223 Predicting molecular evolution of *oxaAb*

224 Given that OxaAb variants with specific amino acid polymorphisms at Ile-129 and Leu-167 have
225 been shown to confer carbapenem resistance in the presence of *ISAbal*, it is reasonable to
226 hypothesise that these polymorphisms may have been selected for in the *A. baumannii*
227 population. To investigate the distribution of these two polymorphisms, a phylogenetic analysis
228 of all available *oxaAb* genes was conducted. Comparison of the *oxaAb* phylogeny with the
229 substitution patterns that result in amino acid changes at the two sites examined showed that

230 substitutions at these sites are likely to have occurred on multiple occasions (**Figure 2**). At
231 position 129, there are 4 alternative codons coding for 4 amino acid changes, suggesting at
232 least 4 independent mutations at this position. The phi test did not detect any significant
233 evidence for recombination within the *oxaAb* genes. Therefore, assuming there is no
234 recombination within these alleles, their distribution across the *oxaAb* phylogeny indicates that
235 mutations at position 129 have occurred on 10 occasions, as seen by alleles carrying the same
236 mutation being separated by alleles that do not share the mutation. Similarly, 3 amino acid
237 changes at position 167 are coded for by 4 different codons, with a phylogenetic distribution
238 suggesting independent mutations arising on 8 occasions. Overall, these data provide strong
239 evidence for selection for changes to the consensus sequence at these sites. Given that no
240 evidence for recombination within the *oxaAb* genes was detected, there are two possibilities
241 that may explain the distribution of polymorphisms: 1) all of the variants have evolved
242 independently and in some instances represent parallel evolution, and 2) there has been
243 recombination of entire *oxaAb* genes between strains, most likely by natural transformation.
244 The most conservative interpretation would be that each different codon only evolved once
245 and any occurrences of the same codon are due to common evolutionary descent or
246 recombination. While we did not detect evidence for recombination within the *oxaAb* genes
247 here, the possibility of between-strain recombination could be examined by a large whole
248 genome analysis, provided sufficient representation of the different *oxaAb* variants were
249 included. At the other extreme, the most liberal interpretation of the data is that each different
250 codon has evolved independently except where there is common evolutionary descent. The
251 relative contributions of independent mutation and recombination to the evolutionary genetics

252 of *oxaAb* remains to be determined; however, our experimental data does show that selection
253 for changes in these two sites do increase carbapenem MIC.

254 Comparing carbapenem resistance signatures in clinical isolates by LC-MS/MS and WGS

255 To determine if upregulation of OxaAb with substitutions in Ile-129 and Leu-167 is the only
256 mechanism of carbapenem resistance in the four resistant clinical isolates (A403, A371, A443
257 and A404), all 10 clinical isolates were analysed for the presence of proteins commonly
258 associated with carbapenem resistance that may be differentially produced in the resistant
259 isolates and from these, porins and efflux pumps were summarised in **Figure 1**.

260 (i) Porins

261 In *A. baumannii*, the major outer membrane protein associated with antimicrobial resistance is
262 a nonspecific slow porin OmpA.⁴³ It is generally accepted that OmpA is involved in the slow
263 diffusion of certain β -lactams across the membrane.^{19,43,44} There were no changes in abundance
264 levels of OmpA in the clinical isolates (compared to CIP70.10) (**Figure 1c**).

265 In terms of porins associated with carbapenem susceptibility, abundance levels of CarO, OmpW
266 and OprD were compared. The disruption of CarO expression in MDR clinical *A. baumannii*
267 isolates by insertion sequences (such as *ISAb1*, *ISAb10*, *ISAb125* and *ISAb825*) has been
268 associated with reduced susceptibility to imipenem^{16,45}, although a reconstituted liposome
269 CarO system has been demonstrated not to transport imipenem.⁴⁶ CarO can be grouped into
270 two major isoforms CarOa and CarOb, with higher specificity for imipenem in the latter.¹⁷ WGS
271 identified all isolates to have intact *carO* genes and no changes to the upstream promoter

272 sequences. A60 and B1 carry CarOa and all other isolates carry CarOb, except A37, A443 and
273 A135 which did not categorise in either groups. Abundance levels of CarO were similar across
274 all isolates except A60, suggesting that there is no critical association between production levels
275 or specific isoforms and carbapenem MIC in these clinical isolates (**Figure 1d**).

276 Loss of OmpW has been implicated with carbapenem resistance, although proteomics studies
277 have also observed increased levels of this porin in MDR isolates.²¹ Another study observed that
278 deletion of *ompW* in carbapenem-susceptible *A. baumannii* ATCC 17978 did not affect
279 imipenem MIC.⁴⁷ No differences in abundance levels were observed (except A90), suggesting
280 that OmpW does not play a role in carbapenem resistance in these isolates (**Figure 1e**).

281 Decreased *oprD* expression has been associated with carbapenem resistance in clinical
282 isolates,⁴⁸⁻⁵⁰ although subsequent knock-out experiments demonstrated no increase in
283 imipenem and meropenem susceptibilities.^{51,52} More recent liposome model studies have
284 shown that OprD does uptake both carbapenems.⁴⁵ Here we observed no significant changes in
285 OprD abundance levels compared to CIP70.10 (**Figure 1f**).

286 (ii) Efflux pumps

287 Overexpression of RND efflux pumps AdeABC and AdeIJK have been associated with aiding
288 carbapenem resistance, although this was not the case in our BM4547 recombinants.⁵³⁻⁵⁵ AdeB
289 was below the level of detection in CIP70.10 and A135, despite confirmation of the gene by
290 WGS. AdeC was not detected in CIP70.10, A37, A60, A230, A403 and A135 and the absence of
291 this gene was confirmed by WGS for CIP70.10, A37, A135 and shown to be truncated for A60.

292 Studies have shown that the *adeABC* operon is not always present in *A. baumannii* strains and
293 amongst the *adeRS-AB*-expressing strains, the outer membrane compartment gene *adeC* is not
294 always present.^{33,56}

295 Adel was not detectable in any of the samples processed despite WGS confirmation. This may
296 suggest (along with the non-detectable AdeBC mentioned above) that these proteins are not
297 expressed in abundance in these particular isolates or a more membrane-specific sample
298 preparation is required for better resolution of membrane proteins, although Yoon and
299 colleagues also reported AdeB to be undetectable in parent strain BM4587 by membrane
300 sample LC-MS/MS.^{54,57}

301 There were no changes in abundance of AdeA, J and K in the carbapenem resistant isolates
302 compared to CIP70.10 (Figure 1g-i). However, there were higher levels in one or more of the
303 proteins in susceptible isolates A60, A230 and A90, with the former two having raised
304 meropenem MICs of 2 mg/L. This suggests that overexpression of these efflux pumps may play
305 a minor role in elevating MICs but the key driver of carbapenem resistance in the clinical
306 isolates under study is the upregulation of OxaAb variants with specific amino acid substitutions.

307 (iii) Other proteins involved in membrane integrity

308 Changes in expression levels of PBPs has been associated with carbapenem resistance, such as
309 the decrease in PBP2 expression levels⁵⁸ or increase in PBP1a and 5 in an imipenem-resistant
310 MDR strain in the presence of imipenem.²⁰ Four PBPs were identified in the LC-MS/MS data –

311 PBP1a, 2, 5 and 6 but no differences were observed between carbapenem susceptible and
312 resistant isolates.

313 Concluding Remarks

314 During the course of this study, other groups published work including clinical isolate
315 characterisation and structural studies that identified residues Trp-222, Ile-129, Pro-130 and
316 Leu-167 in the active site of OxaAb enzymes to contribute to weak carbapenem binding by
317 obstructing the active site from carbapenem interaction, and that substitutions at these sites
318 improve carbapenemase activity.^{26,28,29} While none of the enzymes in this study had Trp-222 or
319 Pro-130 substitutions, this work confirms that OxaAb variants with I129L and L167V
320 substitutions do confer raised carbapenem MICs relative to wild-type genes when all are
321 expressed from the same promoter. When the expression of these enzymes with increased
322 carbapenemase activity are driven by the promoter within *ISAbal*, this confers carbapenem
323 resistance. This was seen in recombinants lacking additional resistance proteins, and also in the
324 resistant clinical isolates, where no additional protein abundance changes predicted to
325 influence carbapenem MIC were observed in the LC-MS/MS data. Hence, we conclude that
326 overproduction of OxaAb variants with enhanced carbapenemase activity due to the
327 substitutions I129L and L167V is sufficient to confer carbapenem resistance in *A. baumannii*
328 with no additional mechanisms required.

330 ACKNOWLEDGEMENTS

331 Genome sequencing was provided by MicrobesNG (<http://www.microbesng.uk>), which is
332 supported by the BBSRC (grant number BB/L024209/1).

333 We would like to thank Laurent Poirel for kindly donating us the strains CIP70.10 and BM4547
334 and Te-Li Chen for providing us with vector pYMAb2.

335 FUNDING

336 This work was funded by Anglia Ruskin University and grants MR/N013646/1 and
337 NE/N01961X/1 from the Antimicrobial Resistance Cross Council Initiative supported by the
338 seven United Kingdom research councils and the National Institute for Health Research.

339 TRANSPARENCY DECLARATIONS

340 None for all authors.

341 REFERENCES

- 342 1. WHO publishes list of bacteria for which new antibiotics are urgently needed. *World Health*
343 *Organ*. [http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-](http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)
344 [which-new-antibiotics-are-urgently-needed](http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed).
- 345 2. Wieland K, Chhatwal P, Vonberg R-P. Nosocomial outbreaks caused by *Acinetobacter*
346 *baumannii* and *Pseudomonas aeruginosa*: Results of a systematic review. *Am J Infect Control*
347 2018; **46**: 643–8.
- 348 3. Potron A, Poirel L, Croizé J *et al*. Genetic and biochemical characterization of the first
349 extended-spectrum CARB-type β -lactamase, RTG-4, from *Acinetobacter baumannii*. *Antimicrob*
350 *Agents Chemother* 2009; **53**: 3010–6.
- 351 4. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas*
352 *aeruginosa* and *Acinetobacter baumannii*: Mechanisms and epidemiology. *Int J Antimicrob*
353 *Agents* 2015; **45**: 568–85.
- 354 5. Bonnin RA, Poirel L, Naas T *et al*. Dissemination of New Delhi metallo- β -lactamase-1-
355 producing *Acinetobacter baumannii* in Europe. *Clin Microbiol Infect Off Publ Eur Soc Clin*
356 *Microbiol Infect Dis* 2012; **18**: E362-365.
- 357 6. Périchon B, Goussard S, Walewski V *et al*. Identification of 50 Class D β -lactamases and 65
358 *Acinetobacter*-derived cephalosporinases in *Acinetobacter* spp. *Antimicrob Agents Chemother*
359 2014; **58**: 936–49.
- 360 7. Héritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion
361 of IS*Aba1* in *Acinetobacter baumannii*. *Clin Microbiol Infect* 2006; **12**: 123–30.
- 362 8. Figueiredo S, Poirel L, Croize J *et al*. In Vivo Selection of Reduced Susceptibility to
363 Carbapenems in *Acinetobacter baumannii* Related to IS*Aba1*-Mediated Overexpression of the
364 Natural blaOXA-66 Oxacillinase Gene. *Antimicrob Agents Chemother* 2009; **53**: 2657–9.
- 365 9. Lopes BS, Amyes SGB. Role of IS*Aba1* and IS*Aba125* in governing the expression of blaADC in
366 clinically relevant *Acinetobacter baumannii* strains resistant to cephalosporins. *J Med Microbiol*
367 2012; **61**: 1103–8.
- 368 10. Scaife W, Young H-K, Paton RH *et al*. Transferable imipenem-resistance in *Acinetobacter*
369 species from a clinical source. *J Antimicrob Chemother* 1995; **36**: 585–6.
- 370 11. Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel Class D β -lactamase with
371 carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob Agents*
372 *Chemother* 2000; **44**: 1556–61.

- 373 12. Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D carbapenemase
374 found in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clin*
375 *Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2005; **11**: 15–23.
- 376 13. Poirel L, Marqué S, Héritier C *et al.* OXA-58, a novel class D β -lactamase involved in
377 resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2005;
378 **49**: 202–8.
- 379 14. Higgins PG, Poirel L, Lehmann M *et al.* OXA-143, a novel carbapenem-hydrolyzing Class D β -
380 lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2009; **53**: 5035–8.
- 381 15. Higgins PG, Pérez-Llarena FJ, Zander E *et al.* OXA-235, a novel class D β -lactamase involved
382 in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2013;
383 **57**: 2121–6.
- 384 16. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-
385 resistant clinical strains of *Acinetobacter baumannii*: natural insertional inactivation of a gene
386 encoding a member of a novel family of beta-barrel outer membrane proteins. *Antimicrob*
387 *Agents Chemother* 2005; **49**: 1432–40.
- 388 17. Catel-Ferreira M, Coadou G, Molle V *et al.* Structure–function relationships of CarO, the
389 carbapenem resistance-associated outer membrane protein of *Acinetobacter baumannii*. *J*
390 *Antimicrob Chemother* 2011; **66**: 2053–6.
- 391 18. Tomás M del M, Beceiro A, Pérez A *et al.* Cloning and Functional Analysis of the Gene
392 Encoding the 33- to 36-Kilodalton Outer Membrane Protein Associated with Carbapenem
393 Resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2005; **49**: 5172–5.
- 394 19. Kwon HI, Kim S, Oh MH *et al.* Outer membrane protein A contributes to antimicrobial
395 resistance of *Acinetobacter baumannii* through the OmpA-like domain. *J Antimicrob Chemother*
396 2017; **72**: 3012–5.
- 397 20. Yun S-H, Choi C-W, Kwon S-O *et al.* Quantitative Proteomic Analysis of Cell Wall and Plasma
398 Membrane Fractions from Multidrug-Resistant *Acinetobacter baumannii*. *J Proteome Res* 2011;
399 **10**: 459–69.
- 400 21. Chopra S, Ramkissoon K, Anderson DC. A systematic quantitative proteomic examination of
401 multidrug resistance in *Acinetobacter baumannii*. *J Proteomics* 2013; **84**: 17–39.
- 402 22. Héritier C, Poirel L, Lambert T *et al.* Contribution of acquired carbapenem-hydrolyzing
403 oxacillinases to carbapenem resistance in *Acinetobacter baumannii*. *Antimicrob Agents*
404 *Chemother* 2005; **49**: 3198–202.
- 405 23. Naas T, Oueslati S, Bonnin RA *et al.* Beta-lactamase database (BLDB) – structure and
406 function. *J Enzyme Inhib Med Chem* 2017; **32**: 917–9.

- 407 24. Lee Y-T, Turton JF, Chen T-L *et al.* First identification of blaOXA-51-like in non-baumannii
408 *Acinetobacter* spp. *J Chemother Florence Italy* 2009; **21**: 514–20.
- 409 25. Chen T-L, Lee Y-T, Kuo S-C *et al.* Emergence and distribution of plasmids bearing the blaOXA-
410 51-like gene with an upstream IS*Aba1* in carbapenem-resistant *Acinetobacter baumannii*
411 isolates in Taiwan. *Antimicrob Agents Chemother* 2010; **54**: 4575–81.
- 412 26. Smith CA, Antunes NT, Stewart NK *et al.* Structural basis for enhancement of
413 carbapenemase activity in the OXA-51 family of Class D β -lactamases. *ACS Chem Biol* 2015; **10**:
414 1791–6.
- 415 27. Mitchell JM, Leonard DA. Common clinical substitutions enhance the carbapenemase
416 activity of OXA-51-like class D β -lactamases from *Acinetobacter* spp. *Antimicrob Agents*
417 *Chemother* 2014; **58**: 7015–6.
- 418 28. June CM, Muckenthaler TJ, Schroder EC *et al.* The structure of a doripenem-bound OXA-51
419 class D β -lactamase variant with enhanced carbapenemase activity. *Protein Sci Publ Protein Soc*
420 2016; **25**: 2152–63.
- 421 29. Schroder EC, Klamer ZL, Saral A *et al.* Clinical variants of the native Class D β -lactamase of
422 *Acinetobacter baumannii* pose an emerging threat through increased hydrolytic activity against
423 carbapenems. *Antimicrob Agents Chemother* 2016; **60**: 6155–64.
- 424 30. Pagano M, Martins AF, Machado ABMP *et al.* Carbapenem-susceptible *Acinetobacter*
425 *baumannii* carrying the IS*Aba1* upstream blaOXA-51-like gene in Porto Alegre, southern Brazil.
426 *Epidemiol Infect* 2013; **141**: 330–3.
- 427 31. Nigro SJ, Hall RM. Does the intrinsic oxaAb (blaOXA-51-like) gene of *Acinetobacter*
428 *baumannii* confer resistance to carbapenems when activated by IS*Aba1*? *J Antimicrob*
429 *Chemother* 2018; **73**: 3518–3520.
- 430 32. Evans BA, Hamouda A, Towner KJ *et al.* OXA-51-like β -lactamases and their association with
431 particular epidemic lineages of *Acinetobacter baumannii*. *Clin Microbiol Infect* 2008; **14**: 268–75.
- 432 33. Marchand I, Damier-Piolle L, Courvalin P *et al.* Expression of the RND-type efflux pump
433 AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system.
434 *Antimicrob Agents Chemother* 2004; **48**: 3298–304.
- 435 34. Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial Susceptibility*
436 *Tests for Bacteria That Grow Aerobically-Eleventh Edition: Approved Standard M07-A11*. CLSI,
437 Wayne, PA, USA, 2018.
- 438 35. Wan Nur Ismah WAK, Takebayashi Y, Findlay J *et al.* Prediction of fluoroquinolone
439 susceptibility directly from whole-genome sequence data by using liquid chromatography-
440 tandem mass spectrometry to identify mutant genotypes. *Antimicrob Agents Chemother* 2018;
441 **62**: e01814-17.

- 442 36. Zhang Z, Schwartz S, Wagner L *et al.* A greedy algorithm for aligning DNA sequences. *J*
443 *Comput Biol J Comput Mol Cell Biol* 2000; **7**: 203–14.
- 444 37. Takebayashi Y, Ismah WAKWN, Findlay J *et al.* Prediction of cephalosporin and carbapenem
445 susceptibility in multi-drug resistant gram-negative bacteria using liquid chromatography-
446 tandem mass spectrometry. *bioRxiv* 2017: 138594.
- 447 38. Kuo S-C, Yang S-P, Lee Y-T *et al.* Dissemination of imipenem-resistant *Acinetobacter*
448 *baumannii* with new plasmid-borne bla(OXA-72) in Taiwan. *BMC Infect Dis* 2013; **13**: 319.
- 449 39. Figueiredo S, Bonnin RA, Poirel L *et al.* Identification of the naturally occurring genes
450 encoding carbapenem-hydrolysing oxacillinases from *Acinetobacter haemolyticus*,
451 *Acinetobacter johnsonii*, and *Acinetobacter calcoaceticus*. *Clin Microbiol Infect* 2012; **18**: 907–13.
- 452 40. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. *Mol Biol*
453 *Evol* 2006; **23**: 254–67.
- 454 41. Evans BA, Amyes SGB. OXA β -lactamases. *Clin Microbiol Rev* 2014; **27**: 241–63.
- 455 42. H eritier C, Poirel L, Fournier P-E *et al.* Characterization of the naturally occurring oxacillinase
456 of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2005; **49**: 4174-9.
- 457 43. Sugawara E, Nikaido H. OmpA is the principal nonspecific slow porin of *Acinetobacter*
458 *baumannii*. *J Bacteriol* 2012; **194**: 4089–96.
- 459 44. Smani Y, F abrega A, Roca I *et al.* Role of OmpA in the multidrug resistance phenotype of
460 *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2014; **58**: 1806–8.
- 461 45. Lee Y, Kim C-K, Lee H *et al.* A novel insertion sequence, IS*Aba10*, inserted into IS*Aba1*
462 adjacent to the bla(OXA-23) gene and disrupting the outer membrane protein gene carO in
463 *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2011; **55**: 361–3.
- 464 46. Zahn M, Bhamidimarri SP, Basl e A *et al.* Structural insights into outer membrane
465 permeability of *Acinetobacter baumannii*. *Structure* 2016; **24**: 221–31.
- 466 47. Catel-Ferreira M, Marti S, Guillon L *et al.* The outer membrane porin OmpW of
467 *Acinetobacter baumannii* is involved in iron uptake and colistin binding. *FEBS Lett* 2016; **590**:
468 224–31.
- 469 48. Dupont M, Pag es J-M, Lafitte D *et al.* Identification of an OprD homologue in *Acinetobacter*
470 *baumannii*. *J Proteome Res* 2005; **4**: 2386–90.
- 471 49. Fern andez-Cuenca F, Smani Y, G omez-S anchez MC *et al.* Attenuated virulence of a slow-
472 growing pandrug-resistant *Acinetobacter baumannii* is associated with decreased expression of
473 genes encoding the porins CarO and OprD-like. *Int J Antimicrob Agents* 2011; **38**: 548–9.

- 474 50. Luo L, Jiang X, Wu Q *et al.* Efflux pump overexpression in conjunction with alternation of
475 outer membrane protein may induce *Acinetobacter baumannii* resistant to imipenem.
476 *Chemotherapy* 2011; **57**: 77–84.
- 477 51. Catel-Ferreira M, Nehmé R, Molle V *et al.* Deciphering the function of the outer membrane
478 protein OprD homologue of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2012; **56**:
479 3826–32.
- 480 52. Smani Y, Pachón J. Loss of the OprD homologue protein in *Acinetobacter baumannii*: Impact
481 on carbapenem susceptibility. *Antimicrob Agents Chemother* 2013; **57**: 677.
- 482 53. Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in *Acinetobacter* spp.
483 *Antimicrob Agents Chemother* 2011; **55**: 947–53.
- 484 54. Yoon E-J, Chabane YN, Goussard S *et al.* Contribution of resistance-nodulation-cell division
485 efflux systems to antibiotic resistance and biofilm formation in *Acinetobacter baumannii*. *mBio*
486 2015; **6**: e00309-15
- 487 55. Zhang Y, Li Z, He X *et al.* Overproduction of efflux pumps caused reduced susceptibility to
488 carbapenem under consecutive imipenem-selected stress in *Acinetobacter baumannii*. *Infect*
489 *Drug Resist* 2017; **11**: 457–67.
- 490 56. Nemeč A, Maixnerová M, van der Reijden TJK *et al.* Relationship between the AdeABC efflux
491 system gene content, netilmicin susceptibility and multidrug resistance in a genotypically
492 diverse collection of *Acinetobacter baumannii* strains. *J Antimicrob Chemother* 2007; **60**: 483–9.
- 493 57. Jiménez-Castellanos J-C, Wan Ahmad Kamil WNI, Cheung CHP *et al.* Comparative effects of
494 overproducing the AraC-type transcriptional regulators MarA, SoxS, RarA and RamA on
495 antimicrobial drug susceptibility in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 2016; **71**:
496 1820–5.
- 497 58. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC *et al.* Relationship between beta-
498 lactamase production, outer membrane protein and penicillin-binding protein profiles on the
499 activity of carbapenems against clinical isolates of *Acinetobacter baumannii*. *J Antimicrob*
500 *Chemother* 2003; **51**: 565–74.
- 501 59. Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and
502 annotation of phylogenetic and other trees. *Nucleic Acids Res* 2016; **44**: W242-245.

503

504 **Table 1. Selected WGS data and carbapenem MICs of clinical *A. baumannii* isolates.**

<i>A. baumannii</i> ID	Geographic Location	OxaAb	GC	Other β -lactamases	ISAb _{a1} OXA	ISAb _{a1} ADC	ISAb _{a125} ADC	AA		MIC (mg/L)	
								129	167	IMP	MEM
CIP70.10	France	(64)	-	ADC-50	-	-	-	I	L	0.125-0.25	0.125-0.5
A37	Singapore	(64)	-	ADC-174	-	+	-	I	L	0.5	0.5
A60	Argentina	(65)	-	ADC-5, TEM-1A, CARB-16	-	+	-	I	L	0.125	2
A230	United Kingdom	(66)	2	ADC-175, Oxa20	-	-	+	I	L	0.5	2
A90	United Kingdom	(69)	1	ADC-11, TEM-1D	-	-	-	I	L	0.125	0.25
B1	Unknown	(51)	-	ADC-180, Oxa10	-	-	-	I	L	1	1
A403	Taiwan	(82)	2	ADC-177, TEM-1D	+	+	-	I	V	32	32
A371	Czech Republic	(83)	2	ADC-30, TEM-1D	+	+	-	L	L	16	32
A443	Slovenia	(107)	1	ADC-176, TEM-1D	+	+	-	I	V	16	16
A404	Poland	(110)	1	ADC-178, TEM-1D	+	+	-	L	L	8	16
A135	Belgium	(111)	-	ADC-179	-	-	-	I	L	0.25	0.25

505

506 Resistant IMP and MEM MIC values (≥ 8 mg/L) in bold. ISAb_{a1} and ISAb_{a125} sequences were found upstream of *oxaAb* and *bla*_{ADC}
 507 (*bla*_{ampC}) genes. GC, global clone; AA, amino acid present at positions 129 and 167, IMP, imipenem; MEM, meropenem.

508

509 **Table 2. Primers used in this study.**

Primer	Sequence (5'-3')
OXA-66-NcoI F	AAACCATGGATGAACATTAAAGCACTC
OXA-66-XhoI R	AAACTCGAGCTATAAAATACCTAATTGTTTC
OXA-111-NcoI F	AAACCATGGATGAACATTAAACACTC
OXA-71-NcoI F	AAACCATGGATGAACATTAAAGCCC
OXA-51-like_XbaI F	AAATCTAGAGTAAAACCTTTATCTATCTCAA
ISAb1_XbaI F	AAATCTAGACTCTGTACACGACAAATT
OXA-51-like_EcoRI R	AAAGAATTCCTATAAAATACCTAATTGTTTC
pYMAb2 Check F	TAACATGAATTTGCCATGG
pYMAb2 Check R	AGCTCGAATTCGGATCC

511 **Table 3. Disc susceptibility test results for selected β -lactams.**

<i>A. baumannii</i> ID	CRO	CTX	CAZ	FEP	IPM	MEM	DOR
CIP70.10	I	I	S	S	S	S	S
A37	R	R	R	S	S	S	S
A60	R	R	I	R	S	S	S
A230	R	R	R	I	S	S	S
A90	I	R	S	S	S	S	S
B1	I	I	S	S	S	S	S
A403	R	R	R	R	R	R	R
A371	R	R	R	R	R	R	R
A443	R	R	R	R	R	R	R
A404	R	R	R	I	R	R	R
A135	S	I	S	S	S	S	S

512 R, resistant; I, intermediate; S, susceptible; CRO, ceftriaxone; CTX, cefotaxime; CAZ, ceftazidime;





513 FEP, cefepime; IPM, imipenem; MEM, meropenem; DOR, doripenem.

515 **Table 4. MIC (in mg/L) of recombinant *A. baumannii* strains carrying various OxaAb enzymes**
 516 **± their natural upstream promoter regions.**





Strain	pYMAb2		pUBYT	
	IPM	MEM	IPM	MEM
CIP70.10 (No Vector)	0.125	0.125	0.125	0.125
Empty Vector	0.25	0.25	0.125	0.25
OxaAb(64)	0.125	0.5	0.5	4
OxaAb(65)	0.125	0.125	0.5	4
OxaAb(66)	0.25	0.25	0.25	4
OxaAb(69)	0.125	0.125	0.25	4
OxaAb(51)	0.06	0.25	0.25	4
OxaAb(82) ▪	2	8	16	64
OxaAb(83) ▪	0.5	2	-	-
OxaAb(107) ▪	2	4	16	64
OxaAb(110) ▪	0.5	2	8	64
OxaAb(111)	0.25	0.125-0.5	0.25	1
BM4547 (No Vector)	0.125	0.5	0.125	0.5
Empty Vector	0.125	0.5	0.125	0.25
OxaAb(64)	0.25	0.125-0.5	0.5	4
OxaAb(65)	0.125	0.5	0.5	4
OxaAb(66)	0.25	0.5	1	8
OxaAb(69)	0.125	0.5	0.5	2
OxaAb(51)	0.25	0.5	0.5	4
OxaAb(82) ▪	2	8	32	> 64
OxaAb(83) ▪	0.5	4	-	-
OxaAb(107) ▪	1	2	64	> 64
OxaAb(110) ▪	0.25	2	32	> 64
OxaAb(111)	0.06	0.125	0.125	4


517
 518 IPM, imipenem; MEM, meropenem. Intermediate (4 mg/L) and resistant (≥ 8 mg/L) MIC values
 519 in bold. “-” indicates strains were not tested. MIC values (n=6) that were variable are
 520 represented by ranges. “▪” highlight OxaAb variants with substitutions in Ile-129 or Leu-167

521




522





524

525 **Figure 1.** Comparison of various resistance determinants by average abundance ratios relative to ribosomal protein (RP). (a) AmpC,
 526 (b) OxaAb, (c) OmpA, (d) CarO, (e) OmpW, (f) OprD, (g) AdeA, (h) AdeJ and (i) AdeK enzymes. Carbapenem resistant clinical isolates
 527 are highlighted with “*”. The absolute abundance values of each protein of interest were divided by the average abundance values
 528 of 30S and 50S ribosomal proteins and averaged to yield ratios with SEM error bars (n=3). Asterisks represent a significant difference
 529 in abundance relative to CIP70.10, based on ≥ 2 -fold difference and t-test ($p < 0.05$).



530

531 **Figure 2.** Cladogram of the nucleotide phylogeny of selected *oxaAb* sequences and their
 532 differences from consensus at amino acid positions 129 and 167. The phylogeny was drawn
 533 using FastTree with all available *oxaAb* sequences and rooted using *oxa213* from *Acinetobacter*
 534 *calcoaceticus* as an outgroup. The sequence labelled accession number AM690768 is an
 535 unnamed variant differing from OxaAb(90) by a single amino acid (at position 129). For clarity,

536 the majority of branches containing genes for OxaAb enzymes that do not have a change from
537 consensus at either position being examined have been hidden, with a minority retained to
538 provide context (shown in italic font). The boxes in the centre represent the amino acid
539 positions, with changes from consensus represented by a filled box. On the right are shown the
540 sequences of amino acids and the corresponding codons. The figure was drawn using iTOL⁵⁹.

Confidential: for peer review only